Equillium (NASDAQ:EQ) COO Sells $362,438.00 in Stock

Key Points

• On March 9, Equillium COO Christine Zedelmayer sold 181,219 shares at $2.00 for $362,438, cutting her ownership by 74.33% to 62,586 shares (about $125,172).
• Zedelmayer has been a consistent seller since December, including notable transactions on Feb. 19 (185,937 shares at $1.76) and Dec. 23 (100,000 shares at $1.50), signaling sustained insider selling.
• Equillium shares traded near $1.99 (up ~1%), with a 50-day/200-day moving average of $1.50/$1.41 and a 52-week range of $0.27–$2.35; analysts’ consensus is a “Hold” with a $3.00 price target and institutions own about 27%.

Equillium, Inc. (NASDAQ:EQ - Get Free Report) COO Christine Zedelmayer sold 181,219 shares of the stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $2.00, for a total transaction of $362,438.00. Following the sale, the chief operating officer directly owned 62,586 shares of the company's stock, valued at approximately $125,172. This trade represents a 74.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Christine Zedelmayer also recently made the following trade(s):

• On Thursday, February 19th, Christine Zedelmayer sold 185,937 shares of Equillium stock. The stock was sold at an average price of $1.76, for a total transaction of $327,249.12.
• On Tuesday, December 23rd, Christine Zedelmayer sold 100,000 shares of Equillium stock. The stock was sold at an average price of $1.50, for a total transaction of $150,000.00.
• On Monday, December 15th, Christine Zedelmayer sold 11,900 shares of Equillium stock. The shares were sold at an average price of $1.31, for a total transaction of $15,589.00.
• On Friday, December 12th, Christine Zedelmayer sold 23,804 shares of Equillium stock. The shares were sold at an average price of $1.34, for a total transaction of $31,897.36.

Equillium Stock Up 1.0%

Shares of EQ traded up $0.02 during midday trading on Wednesday, hitting $1.99. 230,165 shares of the company traded hands, compared to its average volume of 341,426. The firm has a 50 day moving average of $1.50 and a 200-day moving average of $1.41. Equillium, Inc. has a 52 week low of $0.27 and a 52 week high of $2.35.

Hedge Funds Weigh In On Equillium

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Virtu Financial LLC raised its holdings in Equillium by 133.4% during the 3rd quarter. Virtu Financial LLC now owns 23,779 shares of the company's stock valued at $34,000 after buying an additional 13,591 shares during the period. Millennium Management LLC purchased a new position in Equillium during the third quarter worth $35,000. Persistent Asset Partners Ltd bought a new position in Equillium during the third quarter valued at $99,000. Royal Bank of Canada purchased a new stake in shares of Equillium in the fourth quarter valued at $124,000. Finally, Boothbay Fund Management LLC bought a new stake in shares of Equillium in the 3rd quarter worth about $174,000. Hedge funds and other institutional investors own 27.05% of the company's stock.

Analyst Upgrades and Downgrades

EQ has been the subject of several research analyst reports. Stifel Nicolaus began coverage on Equillium in a report on Wednesday, February 25th. They set a "buy" rating and a $5.00 price target for the company. Zacks Research raised Equillium to a "hold" rating in a report on Thursday, February 26th. Wall Street Zen downgraded Equillium from a "hold" rating to a "sell" rating in a research report on Saturday, February 28th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Equillium in a report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Equillium presently has a consensus rating of "Hold" and a consensus price target of $3.00.

About Equillium

Equillium, Inc NASDAQ: EQ is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company's lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium's pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody's established safety profile in earlier clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.